• Who we are

Pipeline

Hits: 21792

Bispecific antibody programs

Bispecific antibody programs

Multispecific antibody programs

Monoclonal antibody programs

Monoclonal antibody programs

Multispecific antibody programs

Back

TM & © Novimmune SA. All rights reserved.
webdesign byhosted climate friendly

First patient dosed with NILK-2301 in Phase I clinical trial

Written by Mei Liang Belhumeur on . Posted in News

First-in-human trial of a CEACAM5xCD3 bispecific κλ body for solid cancer

Read more

LinkedIn